As we head into 2025, Ascendia Pharmaceutical Solutions is gearing up for a prominent presence in San Francisco during one of the biotech industry’s most influential events: the annual JP Morgan Healthcare Conference. The events taking place during JPM mark an exciting opportunity for Ascendia to highlight its expanded capabilities and solidify its position as a leading Contract Development and Manufacturing Organization (CDMO).
Both Dr Jim Huang (CEO) and Bob Bloder (CBO) will be present in SF to connect with pharma/biotech companies. They will be kicking off the new year to establish new relationships (and rekindle old) with a focus on companies in need of complex formulation development and manufacturing CDMO services.
Ascendia will be participating in both the "Biotech Showcase" and "BIO Partnering @ JPM" events that take place during JPM week. These 2 conferences allow for pre-arranged one-on-one meetings. We would like to promote our presence and try to secure more meetings. However, our schedules are filling up and available meeting times are limited. Therefore, it is best to contact us directly via click this link to secure a meeting now.
A Busy Week in San Francisco
While Ascendia won’t be attending the main JP Morgan Healthcare Conference itself, the company will be actively participating in the many ancillary events that surround this prestigious week, including the Biotech Showcase and the BIO Partnering @ JPM 2025 event. These gatherings bring together industry executives, investors, and innovators to explore new business opportunities and discuss the latest developments in biotech and pharma. Click here to schedule a one-on-one via the Bio Partnering system.
During the same week, Ascendia will also host meetings at a dedicated suite at the San Francisco Proper Hotel, providing an ideal setting to connect with investors, as well as new and existing clients. Whether you're attending the JP Morgan Healthcare conference or other other partnering events in San Francisco, Ascendia’s team will be available to discuss partnership opportunities, new projects, and how Ascendia can support the growth of innovative pharmaceutical products. Click here to schedule a time to meet with us in our suite.
Ascendia’s History with JP Morgan, Biotech Showcase and BIO Partnering
Ascendia’s leadership team has a long history of attending these key events. Over the years, Ascendia has used these conferences as a platform to engage in discussions about financial strategies and potential collaborations with pharma and biotech companies. During meetings at the Biotech Showcase and BIO Partnering, Ascendia focuses more on the scientific side, having one-on-one discussions with companies at various stages of development, from startups to large pharma. Ascendia provides solutions for challenges in complex formulation development, optimization, and manufacturing clinical trial materials, making these events a critical part of their business strategy. If you are not already registered, click here to sign up and schedule a time to meet with us via the Biotech Showtech Partnering program.
Exciting Updates for 2025: A New Brand and Expanded Capabilities
One of the most significant updates Ascendia is bringing to the table in 2025 is the company’s rebranding from Ascendia Pharmaceuticals to Ascendia Pharmaceutical Solutions. This shift reflects Ascendia's evolution over the past decade from a formulation development company to a comprehensive solution provider, offering clients end-to-end services from early-stage development through to commercial-scale manufacturing.
The rebrand comes alongside impressive upgrades in Ascendia’s capabilities. In 2024, Ascendia made significant strides in expanding its technology platforms and manufacturing facilities, including new sterile aseptic manufacturing suites and cutting-edge equipment for nano suspension production. Ascendia is the only CDMO in North America with the DeltaVita®Netzsch Mill for large-scale nano-suspension manufacturing, positioning the company as a key player in this growing space.
New Technology and Capabilities: Meeting the Industry’s Most Challenging Needs
In the past year, Ascendia has seen an increase in demand for advanced technologies, particularly in long-acting injectables, LNPs, and other nanotechnologies. The company has responded by investing heavily in these areas, expanding its sterile manufacturing space and adding new equipment to meet the evolving needs of its clients. With a focus on overcoming challenging molecule delivery systems, Ascendia is now poised to take on more complex projects, including scaling up for clinical trials and manufacturing novel molecular entities.
For 2025, Ascendia is ready to help clients facing formulation challenges or needing to scale up their operations quickly. By expanding its capabilities and bringing in new technology, Ascendia ensures it can provide solutions that were not possible a year ago.
Why You Should Meet with Ascendia at These Key Events
As the biotech industry prepares for another dynamic year, Ascendia is in an excellent position to support clients as they move through critical stages of drug development. The company’s rapid response time—projects can typically begin within two weeks of signing a contract—means that companies who meet with Ascendia early in the year will be at the front of the line for access to its new technologies and expanded manufacturing space.
For companies with upcoming needs in formulation development, scale-up, or clinical trial manufacturing, Ascendia’s ability to start new projects quickly makes it a valuable partner. Securing a meeting with Ascendia in January during JPM2025 could ensure that your project is prioritized, helping you stay on track with your development timelines.
Looking Ahead: Industry Trends and Opportunities for 2025
2024 brought significant shifts within the biotech and pharmaceutical industries. The landscape saw acquisitions, shifts in leadership, and an increased focus on domestic U.S.-based development and manufacturing. Ascendia’s U.S. headquarters and its expanded capabilities, place it in a prime position to serve clients who are increasingly looking for reliable, high-quality domestic manufacturing partners.
With the 2025 calendar year bringing new opportunities and challenges, Ascendia is well-prepared to navigate these changes and support clients in bringing innovative therapies to market. Whether you're a West Coast company or an international firm, Ascendia’s expanded capabilities and proactive approach make it a partner of choice.
Join Us in San Francisco!
If you’re planning to be in San Franciso this January to JP Morgan or any of the other parallel events, don’t miss the opportunity to connect with Ascendia’s team. The company’s leadership will be available to discuss new services, capabilities, and how Ascendia can solve your development and manufacturing challenges. Whether you're an established pharmaceutical company or a startup with a promising new therapy, Ascendia is ready to partner with you to help bring your vision to market.
Ascendia looks forward to meeting with industry leaders, new collaborators, and existing clients to discuss how they can help address the most pressing challenges in pharmaceutical development and manufacturing. With new technologies, expanded facilities, and a fresh perspective for 2025, Ascendia is excited about the future and eager to collaborate with the best in the industry.
To learn more about how Ascendia Pharmaceutical Solutions can support your drug development and manufacturing needs, reach out below or contact us directly for a consultation.